Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Have gravitational waves provided the first hint of primordial black holes born during the Big Bang? - 2Select Your Cherished Fish
- 3Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
- 4New movies to watch this weekend: See 'Predator: Badlands' in theaters, rent 'Black Phone 2,' stream Guillermo del Toro's 'Frankenstein' on Netflix
- 5Manual for 6 famous sorts of cheddar
- Coalition led by Iraqi PM al-Sudani wins parliamentary elections
- Why screening for the deadliest cancer in the U.S. misses most cases
- HR exec caught on Coldplay 'kiss cam' with boss finally breaks her silence: 'I made a bad decision and had a couple of High Noons'
- 19 Peculiar Films You Shouldn't Watch With Your Mum
- 23 Most Amusing Messages At any point Sent Among Kids and Their Folks
- Multi-million-euro win in Spanish lottery in doubt due to oversight
- Find the Captivating Professional flowerbeds of the US
- Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- Pick Your Favored kind of soup
